Login
Adicet Bio, Inc. logo

Adicet Bio, Inc.

adicetbio.com

What Do They Do?

Develops engineered, donor-derived immune-cell therapies for people with autoimmune diseases and cancer.

How Do They Make Money?

Revenue comes from fixed fees at agreement start and specified future dates, milestone payments when specified events occur, and royalties on licensed-product sales. Upfront license fees are tied to when the partner can use the intellectual property; bundled licenses and research services can generate revenue over time or at a specific point.

FY2025 revenue

Who Are Their Customers?

Companies work with Adicet through license and collaboration agreements covering intellectual-property licenses and research and development services.

Do Revenues Turn Into Profits?

No. It lost $116.8M in FY2025.

Operating income, FY2025
โˆ’2114% of revenue
โ–ฒ +4% (Loss) vs FY2024 (โˆ’$127.6M)
Net income, FY2025
โˆ’2022% of revenue
โ–ฒ 0% (Loss) vs FY2024 (โˆ’$117.1M)
Free cash flow, FY2025
โˆ’1679% of revenue
โ–ผ โˆ’4% (Loss) vs FY2024 (โˆ’$93.5M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
โ–ฒ +30% (Loss)
vs โˆ’$26.9M in Q3 FY2025

Shrinking. Revenue fell 41% in 4 years, from $9.8M in FY2021 to $5.8M in FY2025, about 12% a year.

Expanded focus to autoimmune diseases The earlier report described the companyโ€™s therapies and pipeline as focused on cancer. The latest report includes autoimmune diseases alongside cancer, with prula-cel being developed for autoimmune conditions.

Who Do They Compete With?

Competes with Kite Pharma and Novartis

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support